Sema4, a Stamford-based genomic-testing biotech company, announced on Monday that it will cut approximately 500 jobs, close its Stamford laboratory and end reproductive health testing.
“We made the difficult decision to exit the reproductive health business and, regretfully, will separate with approximately 500 employees of which roughly half are Connecticut-based colleagues,” a company spokesperson told Patch in an emailed statement.
“We are focused on establishing a scalable path to profitable growth and optimizing for operational and commercial efficiency. These changes better align Sema4 to accomplish those goals and allow us to focus on and accelerate other areas of our business that enable us to impact patients in more powerful ways. Our headquarters remains in Connecticut and we will have a total headcount of approximately 1,100 employees across the state and other locations.”